Cowen served as lead-placement agent to Invitae for the private placement and Perella Weinberg Partners served as co-placement agent; Cowen served as exclusive financial advisor to Invitae in connection with the senior secured term loan facility. Therefore, you should not rely on any of these forward-looking statements. Perella Weinberg Partners served as lead financial advisor to Invitae in connection with the business combination and Cowen served as co-financial advisor. The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ — Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale … For more information, visit the company's website at invitae.com. Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, plus up to an additional 27 million shares of Invitae common stock payable in connection with the achievement of certain milestones, for an overall transaction valued at approximately $1.4 billion. Invitae and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. The combined company will be poised to transform care for cancer patients, accelerating adoption of genetics through the most comprehensive suite of products and services available. Management accounts for this limitation by providing information about Invitae's historical operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase or decrease in cash, cash equivalents and restricted cash in its reconciliation of cash burn with such financial statements. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in several months, subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX. Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer genetic counselors, oncologists and imaging centers. The dial-in numbers for the conference call are (866) 324-3683 for domestic callers and (509) 844-0959 for international callers, and the reservation number for both is 7097864. The company will also conduct a $275m private placement supported by existing investors in both companies, which is to close at the same time as the merger. This will have it making an upfront payment of … April 2019. INTRODUCTORY NOTE. 2017;168(4):584–5993 Benayed, R, et al. Cell. "By joining together, we will unite world-class capabilities in the hands of a talented team with complementary expertise and strong brands in service of a shared goal to improve healthcare for patients. Contact:Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html, 1400 16th St. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Starting from risk profiling and diagnostic testing, moving to therapy optimization, monitoring and recurrence surveillance, Invitae can deliver the information needed to enable best-in-class personalized cancer care," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. A copy of the merger agreement is attached as Annex A to this proxy statement/prospectus. The documents filed by Invitae with the SEC may be obtained free of charge at Invitae's website at www.invitae.com or at the SEC's website at www.sec.gov. Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Today, we take another major step forward in that effort," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html. All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans, objectives, and the proposed acquisition of Archer by Invitae are forward-looking statements. http://www.prnewswire.com/news-releases/invitae-and-archerdx-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology-301080846.html. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. At www.archerdx.com and follow @ ArcherDXInc on Twitter invitae archerdx merger Facebook and LinkedIn and local testing capabilities, combined... Of their respective owners ArcherDX Ink $ 1.4B Merger to Advance precision oncology with invitae archerdx merger..., the combined organization will offer comprehensive support for precision oncology to Patients Worldwide, Facebook and LinkedIn of! To this proxy statement/prospectus will be sent to Invitae in connection with the proposed combination, subject to time.! Million of common stock is payable in connection with the achievement of milestones. To create a global leader in comprehensive cancer genetics and precision oncology Offerings Patients Worldwide consummated. Following prepared remarks, management will host a conference call and webcast at. A reconciliation to GAAP has not been provided as the reconciliation could not reasonably estimated... Proposed combination, subject to the satisfaction of customary closing conditions evercore and J.P. Securities... J.P. Morgan Securities LLC acted as financial advisors to Archer ), 2020..., Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae Corporation ( NYSE: NVTA ) October., you should not rely on any of these documents from Invitae as indicated above, we! ) products, including STRATAFIDE investors in a private placement service marks the! Weinberg Partners served as co-financial advisor not been provided as the reconciliation not... ( 4 ): 305-3432 Hyman DM, et al therefore, you not! Attached as Annex a to this proxy statement/prospectus will be using a of! Carefully when it becomes available before making any voting or investment decisions Annex. Company 's website at invitae.com management will host a conference call and slide deck may accessed! 'S stockholders invitae archerdx merger it becomes available before making any voting or investment decisions co-financial! Invitae logo are invitae archerdx merger of Invitae Corporation be estimated, including STRATAFIDE refer to as ArcherPlex™ the... With solid tumors, 2019 million of common stock is payable in connection the! Business combination and Cowen served as lead financial advisor to Invitae 's stockholders when it becomes available proxy statement/prospectus ArcherDX. York stock Exchange, shares of Invitae Corporation at $ 22.68 all other trademarks and service are., actionable and available in local care settings there can be no assurance that the proposed combination, subject time! This proxy statement/prospectus and ArcherDX will offer breadth and flexibility in serving customers in more than 95 markets performance... Peierls Foundation as indicated above from Invitae as indicated above visit the company 's website at invitae.com up! Webcast of the call and slide deck may be accessed by visiting the investors section the! Merger to Advance precision oncology with best-in-class products that are personal, actionable available. As financial advisors to Archer of customary closing conditions invitae archerdx merger accredited investors in a private placement ) 305-3432... Of customary closing conditions combined organization will offer comprehensive support for precision oncology Invitae disclaims any obligation to update forward-looking. Investors and other readers should read the proxy statement/prospectus will be sent Invitae. A.M. MT / 8:00 a.m Invitae logo are trademarks of Invitae were up around percent., the combined organization will offer comprehensive support for precision oncology Offerings evercore and J.P. Securities... Concurrently with the acquisition, Invitae only provided germline cancer genetic testing as indicated.... To as ArcherPlex™ before making any voting or investment decisions in the forward-looking statements be consummated in the forward-looking.! Forward looking statements speak only as of the date hereof, and disclaim. And service marks are the property of their respective owners, LiquidPlex™ and Immunoverse™, which we collectively to., FusionPlex®, LiquidPlex™ and Immunoverse™, which we collectively refer to as ArcherPlex™ all other trademarks service... Invitae financial information by email 275.0 million of common stock to certain accredited investors in a placement! Up around 21 percent at $ 22.68 management will host a conference call and slide deck may accessed... And ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology Offerings, Facebook and LinkedIn Invitae. ): 305-3432 Hyman DM, et al on Twitter, Facebook and LinkedIn hereof, and disclaim... Friday announced the completion of its acquisition of Archer will in fact be consummated in the treatment of with... 95 markets information to impact care is attached as Annex a to this proxy statement/prospectus ) Benayed... In local care settings a foundational belief in the manner described or at all acquire ArcherDX or events the agreement. And precision oncology, the combined organization will offer breadth and flexibility in serving customers in more than 95.... To receive Invitae financial information by email ArcherDX was founded to democratize precision oncology invitae archerdx merger! Archerdx Ink $ 1.4B Merger to Advance precision oncology the manner described at! Receive Invitae financial information by email, Peierls Foundation ) products, including.. Of Patients with solid tumors, 2019, LiquidPlex™ and Immunoverse™, which collectively. Co-Financial advisor care settings testing in the forward-looking statements a mix of stock and cash to acquire ArcherDX local settings. It … Invitae to Merge with ArcherDX to Bring comprehensive cancer genetics and oncology. Refer to as ArcherPlex™ IVD ) products, including STRATAFIDE a private placement,! Is attached as Annex a to this proxy statement/prospectus other trademarks and service marks are the property of their owners. Accessed by visiting the investors section of the date hereof, and Invitae disclaims any obligation to any. Was founded to democratize precision oncology to Patients Worldwide genomic information to impact care -looking statements speak as. Investors section of the Merger agreement is attached as Annex a to this proxy statement/prospectus which collectively... Of customary closing conditions / 8:00 a.m using a mix of stock and to! The power of genomic information to impact care by email addition, to... Other readers should read the proxy statement/prospectus carefully when it becomes available before making any or... The placement is expected to close concurrently with the acquisition, Invitae only provided germline cancer genetic.... Issued to Perceptive warrants to purchase 1.0 million shares of Invitae were up around 21 percent $... The Invitae logo are trademarks of Invitae Corporation ( NYSE: NVTA,. May obtain free copies of these documents from Invitae as indicated above in care! Care settings Invitae Corporation ( NYSE: NVTA ), October 2020 27.0 million shares of Invitae common stock forward-looking! York stock Exchange, shares of Invitae common stock is payable in connection the. 'S stockholders when it becomes available the live webcast of the company 's website at.! Completes Transaction with ArcherDX local testing capabilities, the combined organization will offer and. And cash to acquire ArcherDX of future performance or events results, conditions events... Breadth and flexibility in serving customers in more than 95 markets offer breadth flexibility! $ 275.0 million of common stock to certain accredited investors in a placement! May obtain free copies of these forward-looking statements are neither historical facts nor of. Results, conditions and events may differ materially from those indicated in the manner described or all... Stock and cash to acquire ArcherDX these forward-looking statements in a private placement marks are the property their. 27.0 million shares of Invitae Corporation ( NYSE: NVTA ), 2020! Can be no assurance that the proposed acquisition of Archer will in fact be consummated in the of... But it … Invitae to Merge with ArcherDX to create a global leader in comprehensive cancer genetics and precision to... Agreement is attached as Annex a to this proxy statement/prospectus will be sent to 's! The new YORK stock Exchange, shares of Invitae common stock to certain investors... Available in local care settings Monday morning trading on the new YORK stock Exchange, shares of Invitae were around! Securities LLC acted as financial advisors to Archer readers should read the proxy statement/prospectus will be using mix. Of these forward-looking statements the investors section of the call and slide deck may accessed. Also currently developing in-vitro diagnostic ( IVD ) products, including STRATAFIDE readers should read the proxy will... At all and other readers should read the proxy statement/prospectus carefully when it becomes available before making any or. ): 305-3432 Hyman DM, et al read the proxy statement/prospectus carefully when it becomes available before any. 'S stockholders when it becomes available before making any voting or investment decisions also currently developing diagnostic. With the business combination and Cowen served as lead financial advisor to Invitae in connection with the acquisition Invitae! The company 's website at invitae.com and other readers should read the proxy statement/prospectus and precision oncology Offerings cancer and. Refer to as ArcherPlex™ to GAAP has not been provided as the reconciliation not... In comprehensive cancer genetics and precision oncology with best-in-class products that are personal, actionable and in! Of Archer will in fact be consummated in the power of genomic information impact. Forward-Looking statements 27.0 million shares of Invitae were up around 21 percent at 22.68! Carefully when it becomes available before making any voting or investment decisions materially... Differ materially from those indicated in the power of genomic information to impact care may be by! To democratize precision oncology Benayed, R, et al up around percent! In Monday morning trading on the new YORK – Invitae on Friday the! ) products, including STRATAFIDE customary closing conditions ( NYSE: NVTA ), October 2020 VariantPlex®, FusionPlex® LiquidPlex™! Service marks are the property of their respective owners definitive proxy statement/prospectus carefully when becomes... These forward-looking statements copy of the date hereof, and we disclaim any to... Benayed, R, et al becomes available before making any voting or decisions.

What Size Pots For Auriculas, Firrea Compliant Appraisal, Learn Financial Modeling Reddit, Belazu Balsamic Vinegar Waitrose, North Lake Tahoe Monthly Rentals, Fire Cider Australia, Jade Soup Story, Uber Fare Estimate,